Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis

BackgroundChronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is an etiologically unexplained disorder characterised by irregularities in various aspects of the immunological function. Presently, it is unknown whether these immunological changes remain consistent over time. This study investigates Natural Killer (NK) cell cytotoxic activity, NK cell subsets (CD56brightCD16- and CD56dimCD16+) and cytokines, over the course of a12 month period in patients with CFS/ME.MethodsThe participants in the study comprised 65 (47.2 ± 11.5 years) CFS/ME participants and 21 (45.2 ±9.3 years) non-fatigued controls. Flow cytometry protocols were used to assess NK subsets and NK cytotoxic activity at various time points that included baseline (T1), 6 (T2) and 12 months (T3). Cytokine secretions were measured following mitogenic stimulation of peripheral blood mononuclear cells.ResultsNK cytotoxic activity was significantly decreased in the CFS/ME patients at T1, T2 and T3 compared to the non-fatigued group. Additionally, in comparison to the non-fatigued controls, the CFS/ME group had significantly lower numbers of CD56brightCD16- NK cells at both T1 and T2. Interestingly, following mitogenic stimulation, cytokine secretion revealed significant increases in IL-10, IFN-γ and TNF-α at T1 in the CFS/ME group. A significant decrease was observed at T2 in the CFS/ME group for IL-10 and IL-17A while at T3, IL-2 was increased in the CFS/ME group in comparison to the non-fatigued controls. Overall cytotoxic activity was significantly decreased at T3 compared to T1 and T2. CD56brightCD16- NK cells were much lower at T2 compared to T1 and T3. IL-10 and IL-17A secretion was elevated at T2 in comparison to T1 and T3.ConclusionThese results confirm decreases in immune function in CFS/ME patients, suggesting an increased susceptibility to viral and other infections. Furthermore, NK cytotoxic activity may be a suitable biomarker for diagnosing CFS/ME as it was consistently decreased during the course of the 12 months study.

[1]  S. Wessely,et al.  Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. , 1997, Clinical immunology and immunopathology.

[2]  G. Ricevuti,et al.  Immunological aspects of chronic fatigue syndrome. , 2009, Autoimmunity reviews.

[3]  A. Moretta,et al.  NK cells and their receptors during viral infections. , 2011, Immunotherapy.

[4]  J. Steinke,et al.  Immunologic messenger molecules: cytokines, interferons, and chemokines. , 2010, The Journal of allergy and clinical immunology.

[5]  W. Paul,et al.  CD4 T cells: fates, functions, and faults. , 2008, Blood.

[6]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[7]  ANTAGONISTS OF MONOCYTE CHEMOATTRACTANT PROTEIN 1 IDENTIFIED BY MODIFICATION OF FUNCTIONALLY CRITICAL NH2-TERMINAL RESIDUES , 1995 .

[8]  L. Fouser,et al.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.

[9]  Kevin Maher,et al.  Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 , 2010, PloS one.

[10]  Eric Vivier,et al.  Natural Killer Cell Signaling Pathways , 2004, Science.

[11]  S. Wessely,et al.  High levels of type 2 cytokine‐producing cells in chronic fatigue syndrome , 2004, Clinical and experimental immunology.

[12]  U. Tirelli,et al.  Immunological Abnormalities in Patients with Chronic Fatigue Syndrome , 1994, Scandinavian journal of immunology.

[13]  A. Moretta,et al.  Bridging innate NK cell functions with adaptive immunity. , 2011, Advances in experimental medicine and biology.

[14]  J. Gong,et al.  Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues , 1995, Journal of Experimental Medicine.

[15]  A. Masuda,et al.  Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. , 1994, Psychosomatic medicine.

[16]  Ethan M. Shevach,et al.  Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.

[17]  L. Turka,et al.  TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. , 2010, Blood.

[18]  J. Bonnefoy,et al.  Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. , 1999, Cytometry.

[19]  N. Klimas,et al.  Chronic fatigue syndrome: Inflammation, immune function, and neuroendocrine interactions , 2007, Current rheumatology reports.

[20]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[21]  K. Finlayson,et al.  VPAC and PAC receptors: From ligands to function. , 2009, Pharmacology & therapeutics.

[22]  B. Wąsowska.  Cross-talk between innate and adaptive immune responses in infection, transplant and autoimmune models. , 2011, Current opinion in organ transplantation.

[23]  M. Baggiolini,et al.  Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. , 1996, Journal of immunology.

[24]  T. Kawai,et al.  Identification of Marker Genes for Differential Diagnosis of Chronic Fatigue Syndrome , 2022 .

[25]  M. Fletcher,et al.  Chronic fatigue syndrome is associated with diminished intracellular perforin , 2005, Clinical and experimental immunology.

[26]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[27]  A. Komaroff,et al.  Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression , 2005, Clinical and experimental immunology.

[28]  W. Paul,et al.  Independent roles for IL-2 and GATA-3 in stimulating naive CD4+ T cells to generate a Th2-inducing cytokine environment , 2005, The Journal of experimental medicine.

[29]  M. Caligiuri,et al.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. , 2003, Blood.

[30]  I. Hickie,et al.  Cell‐mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression , 1992, Clinical and experimental immunology.

[31]  A. Tyznik,et al.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.

[32]  R. Biassoni,et al.  Human natural killer cell receptors and co‐receptors , 2001, Immunological reviews.

[33]  M. Fletcher,et al.  Immunologic abnormalities in chronic fatigue syndrome , 1990, Journal of clinical microbiology.

[34]  R. Biassoni.  Human Natural Killer Receptors, Co‐Receptors, and Their Ligands , 2009, Current protocols in immunology.

[35]  P. Forsberg,et al.  Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. , 1992, The Journal of infectious diseases.

[36]  O. Mandelboim,et al.  The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells , 1997, Nature.

[37]  Gordon Broderick,et al.  A formal analysis of cytokine networks in Chronic Fatigue Syndrome , 2010, Brain, Behavior, and Immunity.

[38]  R. Clark,et al.  Old meets new: the interaction between innate and adaptive immunity. , 2005, The Journal of investigative dermatology.

[39]  A. De Maria,et al.  Involvement of Activating NK Cell Receptors and Their Modulation in Pathogen Immunity , 2011, Journal of biomedicine & biotechnology.

[40]  Jay K Kolls,et al.  The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation , 2022 .

[41]  O. Baskurt,et al.  Immune and hemorheological changes in Chronic Fatigue Syndrome , 2010, Journal of Translational Medicine.

[42]  J. Peter,et al.  Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  M. Antoni,et al.  Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  P. Gray,et al.  Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4* , 1998, The Journal of Biological Chemistry.

[45]  R. D. Hatton,et al.  IL-17 family cytokines and the expanding diversity of effector T cell lineages. , 2007, Annual review of immunology.

[46]  J. Maris,et al.  Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. , 2010, Cancer research.

[47]  A. Morton,et al.  Reliability of physiological, psychological, and cognitive variables in chronic fatigue syndrome , 2005, Research in sports medicine.

[48]  W. Katon,et al.  Chronic fatigue. A prospective clinical and virologic study. , 1990, JAMA.

[49]  C. L. Warner,et al.  Predictive immunophenotypes: Disease‐related profile in chronic fatigue syndrome , 2003, Cytometry. Part B, Clinical cytometry.

[50]  J. Vecchiet,et al.  Study of Immune Alterations in Patients with Chronic Fatigue Syndrome with Different Etiologies , 2004, International journal of immunopathology and pharmacology.

[51]  N. Klimas,et al.  Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis , 2011, Journal of Translational Medicine.

[52]  G. Bleijenberg,et al.  Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. , 1996, The Journal of infectious diseases.

[53]  L. Doornen,et al.  Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents , 2007, Brain, Behavior, and Immunity.

[54]  G. Canonica,et al.  Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. , 2008, The Journal of allergy and clinical immunology.

[55]  J. Myśliwska,et al.  NK cell compartment in patients with coronary heart disease , 2007, Immunity & Ageing.

[56]  I. Hickie,et al.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. , 1994, Annals of internal medicine.

[57]  Ian Hickie,et al.  The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study , 1994, Annals of Internal Medicine.

[58]  M. Frémont,et al.  Lower frequency of IL-17F sequence variant (His161Arg) in chronic fatigue syndrome patients. , 2008, Biochemical and biophysical research communications.

[59]  D. MacGlashan,et al.  Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner. , 1999, The Journal of allergy and clinical immunology.

[60]  J. Levy,et al.  Immunologic abnormalities associated with chronic fatigue syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  Mary Ann Fletcher,et al.  Plasma cytokines in women with chronic fatigue syndrome , 2009, Journal of Translational Medicine.